{
    "info": {
        "nct_id": "NCT06040320",
        "official_title": "A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)",
        "inclusion_criteria": "* Previously untreated biopsy-confirmed CD20-positive monomorphic post-transplant lymphoproliferative disorder (or CD20-positive lymphoma associated with immune deficiency) arising after solid organ or hematopoietic stem cell transplant. This may be defined by either the 2016 World Health Organization classification of lymphoid neoplasms or the 2022 International consensus Classification of Mature Lymphoid Neoplasms or the 2022 World Health Organization classification.\n* At least 18 years of age.\n* ECOG performance status ≤ 3.\n* Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator) as defined below:\n\n  * Absolute neutrophil count ≥ 1.0 K/cumm\n  * Platelets ≥ 75 K/cumm\n  * Hemoglobin ≥ 8.0 g/dL\n  * Total bilirubin < 1.5 x IULN\n  * AST(SGOT)/ALT(SGPT) < 2.5 x IULN\n  * Creatinine clearance > 30 mL/min measured or by Cockcroft-Gault\n* Note: Patients with extensive bone marrow involvement by lymphoma and/or disease-related cytopenias may be enrolled if the following criteria are met:\n\n  * ANC ≥ 0.5 K/cumm\n  * Platelets ≥ 50 K/cumm\n  * Hemoglobin ≥ 7.0 g/dL\n* The effects of polatuzumab vedotin and rituximab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect pregnancy while participating in this study, the participant must inform the treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Active central nervous system involvement with lymphoma / PTLD.\n* Current grade ≥ 2 peripheral neuropathy.\n* Current ejection fraction < 40% on transthoracic echocardiogram or multigated acquisition (MUGA) scan\n* Subjects with history of concurrent second cancers requiring active, ongoing systemic treatment with the following exceptions:\n\n  * Patients with non-melanoma skin cancer or carcinoma in situ of the cervix will not be excluded.\n  * Patients with previous malignancies are eligible if disease-free for > 2 years.\n  * Patients on long term hormonal therapy to prevent recurrence of a prior cancer (e.g., hormonal therapy for breast cancer) will not be excluded.\n* Currently receiving any other investigational agents or received any investigational agents during the 4 weeks prior to the first dose of polatuzumab vedotin.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to polatuzumab vedotin, rituximab, or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, fungal, viral, parasitic, or mycobacterial), interstitial lung disease, active non-infectious pneumonitis, congestive heart failure NYHA grade ≥ 3, unstable angina pectoris, or cardiac arrhythmia.\n* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to C1D1\n* Patients with HIV are eligible provided the meet the following criteria:\n\n  * On antiretroviral regimen and stable on that regimen\n  * Healthy from an HIV perspective\n  * CD4 count > 250 cells/mcL\n  * Minimal anticipated interactions or overlapping toxicity with polatuzumab vedotin or rituximab\n  * HIV viral load < 200 copies/mm3 by standard clinical assays\n* Active hepatitis B infection.\n\n  * Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation.\n* Active hepatitis C infection.\n\n  * Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation.\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Hemoglobin ≥ 8.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator) as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator)",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless due to underlying lymphoma per the investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator)",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless due to underlying lymphoma per the investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously untreated biopsy-confirmed CD20-positive monomorphic post-transplant lymphoproliferative disorder (or CD20-positive lymphoma associated with immune deficiency) arising after solid organ or hematopoietic stem cell transplant. This may be defined by either the 2016 World Health Organization classification of lymphoid neoplasms or the 2022 International consensus Classification of Mature Lymphoid Neoplasms or the 2022 World Health Organization classification.",
            "criterions": [
                {
                    "exact_snippets": "Previously untreated",
                    "criterion": "treatment history",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy-confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "CD20-positive monomorphic post-transplant lymphoproliferative disorder (or CD20-positive lymphoma associated with immune deficiency)",
                    "criterion": "disease type",
                    "requirements": [
                        {
                            "requirement_type": "disease",
                            "expected_value": [
                                "CD20-positive monomorphic post-transplant lymphoproliferative disorder",
                                "CD20-positive lymphoma associated with immune deficiency"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "arising after solid organ or hematopoietic stem cell transplant",
                    "criterion": "transplant history",
                    "requirements": [
                        {
                            "requirement_type": "prior transplant",
                            "expected_value": [
                                "solid organ transplant",
                                "hematopoietic stem cell transplant"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "This may be defined by either the 2016 World Health Organization classification of lymphoid neoplasms or the 2022 International consensus Classification of Mature Lymphoid Neoplasms or the 2022 World Health Organization classification.",
                    "criterion": "diagnostic classification system",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": [
                                "2016 World Health Organization classification of lymphoid neoplasms",
                                "2022 International consensus Classification of Mature Lymphoid Neoplasms",
                                "2022 World Health Organization classification"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance > 30 mL/min measured or by Cockcroft-Gault",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance > 30 mL/min measured or by Cockcroft-Gault",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "measured",
                                "Cockcroft-Gault"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The effects of polatuzumab vedotin and rituximab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect pregnancy while participating in this study, the participant must inform the treating physician immediately.",
            "criterions": [
                {
                    "exact_snippets": "women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": [
                                "women of childbearing potential",
                                "men"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry and for the duration of study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin < 1.5 x IULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin < 1.5 x IULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x IULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 7.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 7.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 50 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 50 K/cumm",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 1.0 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1.0 K/cumm",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 75 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 75 K/cumm",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST(SGOT)/ALT(SGPT) < 2.5 x IULN",
            "criterions": [
                {
                    "exact_snippets": "AST(SGOT)/ALT(SGPT) < 2.5 x IULN",
                    "criterion": "AST (SGOT)",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "x IULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST(SGOT)/ALT(SGPT) < 2.5 x IULN",
                    "criterion": "ALT (SGPT)",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "x IULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and willingness to sign an IRB approved written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign an IRB approved written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "document type",
                            "expected_value": "IRB approved written informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients with extensive bone marrow involvement by lymphoma and/or disease-related cytopenias may be enrolled if the following criteria are met:",
            "criterions": [
                {
                    "exact_snippets": "extensive bone marrow involvement by lymphoma",
                    "criterion": "bone marrow involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": "extensive"
                        }
                    ]
                },
                {
                    "exact_snippets": "disease-related cytopenias",
                    "criterion": "cytopenias",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "disease-related"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 18 years of age.",
            "criterions": [
                {
                    "exact_snippets": "At least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC ≥ 0.5 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 0.5 K/cumm",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 3.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active hepatitis B infection.",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current ejection fraction < 40% on transthoracic echocardiogram or multigated acquisition (MUGA) scan",
            "criterions": [
                {
                    "exact_snippets": "Current ejection fraction < 40% on transthoracic echocardiogram or multigated acquisition (MUGA) scan",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with previous malignancies are eligible if disease-free for > 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Patients with previous malignancies ... eligible if disease-free for > 2 years",
                    "criterion": "previous malignancies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "disease-free for > 2 years",
                    "criterion": "disease-free interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently receiving any other investigational agents or received any investigational agents during the 4 weeks prior to the first dose of polatuzumab vedotin.",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving any other investigational agents",
                    "criterion": "investigational agent use (current)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "received any investigational agents during the 4 weeks prior to the first dose of polatuzumab vedotin",
                    "criterion": "investigational agent use (recent)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minimal anticipated interactions or overlapping toxicity with polatuzumab vedotin or rituximab",
            "criterions": [
                {
                    "exact_snippets": "Minimal anticipated interactions ... with polatuzumab vedotin",
                    "criterion": "interactions with polatuzumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Minimal anticipated ... overlapping toxicity with polatuzumab vedotin",
                    "criterion": "overlapping toxicity with polatuzumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Minimal anticipated interactions ... with ... rituximab",
                    "criterion": "interactions with rituximab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Minimal anticipated ... overlapping toxicity with ... rituximab",
                    "criterion": "overlapping toxicity with rituximab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* On antiretroviral regimen and stable on that regimen",
            "criterions": [
                {
                    "exact_snippets": "On antiretroviral regimen",
                    "criterion": "antiretroviral regimen",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable on that regimen",
                    "criterion": "antiretroviral regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with HIV are eligible provided the meet the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Patients with HIV are eligible",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to C1D1",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to C1D1",
                    "criterion": "pregnancy test result (for women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to C1D1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation.",
            "criterions": [
                {
                    "exact_snippets": "hepatitis B surface antigen (HBsAg) negative",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B core antibody (HBcAb) positive",
                    "criterion": "hepatitis B core antibody (HBcAb)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR)",
                    "criterion": "hepatitis B virus (HBV) polymerase chain reaction (PCR)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with non-melanoma skin cancer or carcinoma in situ of the cervix will not be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients with non-melanoma skin cancer ... will not be excluded.",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinoma in situ of the cervix will not be excluded.",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, fungal, viral, parasitic, or mycobacterial), interstitial lung disease, active non-infectious pneumonitis, congestive heart failure NYHA grade ≥ 3, unstable angina pectoris, or cardiac arrhythmia.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection (bacterial, fungal, viral, parasitic, or mycobacterial)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "fungal",
                                "viral",
                                "parasitic",
                                "mycobacterial"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure NYHA grade ≥ 3",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation.",
            "criterions": [
                {
                    "exact_snippets": "Patients who are positive for hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus (HCV) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be negative for HCV by PCR",
                    "criterion": "HCV by PCR",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CD4 count > 250 cells/mcL",
            "criterions": [
                {
                    "exact_snippets": "CD4 count > 250 cells/mcL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients on long term hormonal therapy to prevent recurrence of a prior cancer (e.g., hormonal therapy for breast cancer) will not be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients on long term hormonal therapy to prevent recurrence of a prior cancer (e.g., hormonal therapy for breast cancer)",
                    "criterion": "long term hormonal therapy to prevent recurrence of a prior cancer",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with history of concurrent second cancers requiring active, ongoing systemic treatment with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "history of concurrent second cancers requiring active, ongoing systemic treatment",
                    "criterion": "concurrent second cancers",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system involvement with lymphoma / PTLD.",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system involvement with lymphoma / PTLD",
                    "criterion": "central nervous system involvement with lymphoma / PTLD",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Healthy from an HIV perspective",
            "criterions": [
                {
                    "exact_snippets": "Healthy from an HIV perspective",
                    "criterion": "HIV health status",
                    "requirements": [
                        {
                            "requirement_type": "health status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HIV viral load < 200 copies/mm3 by standard clinical assays",
            "criterions": [
                {
                    "exact_snippets": "HIV viral load < 200 copies/mm3",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 200,
                                "unit": "copies/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current grade ≥ 2 peripheral neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "Current grade ≥ 2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to polatuzumab vedotin, rituximab, or other agents used in the study.",
            "criterions": [
                {
                    "exact_snippets": "A history of allergic reactions attributed to compounds of similar chemical or biologic composition to polatuzumab vedotin",
                    "criterion": "allergic reactions to compounds similar to polatuzumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ... rituximab",
                    "criterion": "allergic reactions to compounds similar to rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of allergic reactions attributed to ... other agents used in the study",
                    "criterion": "allergic reactions to other agents used in the study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.",
            "criterions": [
                {
                    "exact_snippets": "Any serious medical condition ... precludes the patient's safe participation in and completion of the study",
                    "criterion": "serious medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormality in clinical laboratory tests ... precludes the patient's safe participation in and completion of the study",
                    "criterion": "abnormality in clinical laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, ... could affect compliance with the protocol or interpretation of results",
                    "criterion": "serious medical condition or abnormality in clinical laboratory tests affecting compliance or interpretation",
                    "requirements": [
                        {
                            "requirement_type": "effect on compliance or interpretation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}